News | Heart Failure | February 04, 2016

Sleep Apnea Treatment Associated with Reduced Heart Failure Readmissions

Early diagnosis with patient treatment compliance found to reduce six-month readmission rates

sleep apnea, heart failure readmissions, Thomas Jefferson University study

February 4, 2016 — Early diagnosis and treatment of sleep apnea may reduce six-month readmissions for patients hospitalized with heart failure, according to research recently published online by the American Journal of Cardiology.

“Our research showed that early recognition and treatment of patients hospitalized with decompensated congestive heart failure is associated with a reduction in readmissions, for patients who use their positive airway pressure (PAP) therapy on a regular basis,” said first author Sunil Sharma, M.D., FAASM, associate professor of pulmonary medicine in the Sidney Kimmel Medical College at Thomas Jefferson University. “Importantly, hospitals can implement cost-effective screening programs to catch sleep apnea in hospitalized, high-risk patients.”

Sharma and the team screened patients admitted to the hospital with heart failure, for underlying sleep disordered breathing. Of the 75 patients that followed up with an outpatient polysomnography, the gold standard test, 70 received the diagnosis of sleep disordered breathing. Over the next six months, the team tracked patients’ PAP compliance, emergency room visits and readmissions. Compliance was monitored objectively by the device computer and defined as a minimum of four hours of use, 70 percent of the time, for four weeks consecutively or more during the first three months of therapy.

By comparing pre- and post-treatment readmissions in compliant (n=37) and non-compliant patients (n=33), the researchers found a reduction in hospital visits for those who used their PAP regularly over a period of six months.

“Physicians should be on the lookout for sleep apnea in patients with heart failure with the goal of diagnosing and treating early, which might help prevent readmissions and emergency room visits,” Sharma said. “Multi-center, randomized studies are needed to replicate and validate these findings.”

For more information: www.ajconline.org


Related Content

Feature | Heart Failure | Rohit Sood, MD, PhD

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect ...

Home February 12, 2026
Home
News | Heart Failure

Feb. 3, 2026 — Bristol Myers Squibb has launched "Change the Target. Change What’s Possible," an educational campaign ...

Home February 03, 2026
Home
News | Heart Failure

Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac ...

Home January 27, 2026
Home
News | Heart Failure

Jan. 6, 2026 — Millions of Americans living with heart failure are not receiving medications that have been proven for ...

Home January 10, 2026
Home
News | Heart Failure

Dec. 16,2025 — The European Society of Cardiology (ESC) has welcomed the adoption of the Safe Hearts Plan, a landmark ...

Home December 23, 2025
Home
News | Heart Failure

Dec. 18, 2025 — Heartflow, Inc., a provider of AI technology for coronary artery disease (CAD), has announced the ...

Home December 22, 2025
Home
News | Heart Failure

Dec. 18, 2025 – Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home December 18, 2025
Home
News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
Subscribe Now